Searchable abstracts of presentations at key conferences in endocrinology

ea0005p37 | Clinical Case Reports | BES2003

A case of ectopic ACTH with severe opportunistic infection

Hatfield E , Pal S , Meeran K , Williams G , Todd J

A case of ectopic ACTH with severe opportunistic infectionECI Hatfield, S Pal, K Meeran, G Williams, JF Todd.Endocrine Unit, Imperial College, Hammersmith Hospital, London, UKA twenty six year old female presented with symptoms and signs suggestive of Cushing's Syndrome. Initial investigations showed hypokalaemia (potassium 2.3nmol/L), elevated urinary free cortisols, (3400, 18,000, 31,000 nmol/24 hour (NR <270)), diabetes (fasting glucose =9 mmol/L), loss of di...

ea0037gp.29.07 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Penetrance and optimal surveillance for SDHB mutation carriers

Eijkelenkamp Karin , Osinga Thamara E , de Jong Mirjam M , Sluiter Wim J , Dullaart Robin P F , Links Thera P , Kerstens Michiel N , van der Horst-Schrivers Anouk N A

Context: Germline mutations of the gene encoding succinate dehydrogenase subunit B (SDHB) predispose to head and neck paraganglioma (HNPGL), sympathetic PGL, phaeochromocytoma and renal cell carcinoma for which regular surveillance is required. SDHB-associated tumors harbor germline and somatic mutations, consistent with Knudson’s two-hit hypothesis stating that the combination of an inactivating germline mutation as a first hit and somatic loss of funct...

ea0064034 | An unusual case of pubertas tarda: IGSF-1 deficiency syndrome | BES2019

An unusual case of pubertas tarda: IGSF-1 deficiency syndrome

Matthys I , Taes Y , Callewaert B , De Schepper J

Background aim of the work: IGSF-1 encodes a plasma membrane immunoglobulin superfamily glycoprotein that is abundant in the pituitary and testis. Loss-of-function causes an X-linked syndrome which is mainly characterized by congenital hypothyroidism and macroorchidism.[1,2] Because of its relatively recent discovery and its very rare incidence, the time to diagnosis is often long. We present a case of IGSF1 deficiency case where it took 6 years before diagnosis was made. With...

ea0057030 | Preoperative treatment of benign insulinoma: diazoxide or lanreotide? | BES2018

Preoperative treatment of benign insulinoma: diazoxide or lanreotide?

Gilliaux Q , Hanon F , Bertrand C , Donckier J

Introduction: Insulinoma is a rare neuroendocrine tumour of the pancreas. Its resection is the only curative treatment. However, medical therapy may be needed to prevent severe preoperative hypoglycaemia, when surgery is contraindicated, delayed or refused and in case of unresectable metastatic disease. To our knowledge, a comparison between these two medications has never been performed.Case report: We describe the case of a 27-year-old patient without ...

ea0019p93 | Clinical practice/governance and case reports | SFEBES2009

Near-normoglycemic remission in diabetic ketoacidosis: a case report

Woodhead N , Rees J , Jose B , De P

Ketosis-prone, Jamaica (J) type diabetes is an uncommon form of diabetes described in a sub-population of mainly Afro-Caribbean patients who often present acutely with diabetic ketoacidosis (DKA) but during follow up demonstrate clinical, metabolic, and immunologic features of Type II diabetes. We present such a case.A 37-year old Afro-Caribbean man with a family history of Type II diabetes presented with polyuria, polydipsia and weight loss. He was over...

ea0011p214 | Comparative endocrinology | ECE2006

Assessment of oxidative stress in patients with polycystic ovarian syndrome treated with either Orlistat or Metformin

Shepherd J , Jayagopal V , Kilpatrick ES , Atkin SL

Orlistat and Metformin have both been shown to be beneficial in the treatment of Polycystic Ovarian Syndrome (PCOS), however, because Orlistat works by decreasing the absorption of dietary lipids, there is the potential to decrease absorption of lipophilic antioxidant substances with consequent decreased protection from oxidative stress. The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on oxidative stress in pat...

ea0003oc1 | Genetics: New Insights into Endocrine Disease | BES2002

All in the family: Site and gender specificity of the genetic control of bone mineral density

Duncan E , Cardon L , Wass J , Brown M

Bone mineral density (BMD) is a highly heritable trait. We sought to investigate site and gender specificity of BMD inheritance in general pedigrees.Probands with primary osteoporosis and low BMD relative to an age- and sex- matched cohort (z-score <-2.0 at either lumbar spine (LS) or femoral neck (FN)) were identified from the Nuffield Orthopaedic Centre (Oxford UK) (45 male, 102 female). All available first- and second-degree relatives were recrui...

ea0031oc4.8 | Obesity, metabolism and bone | SFEBES2013

Peptide YY regulates bone mineral content and strength

Brassill M J , Rahman S A , Boyde A , Batterham R L , Williams G R , Assett J H D B

Bone loss in anorexia nervosa and following bariatric surgery is associated with an elevated circulating concentration of the gastrointestinal anorexigenic hormone peptide YY (PYY), which acts principally via the Y1R and Y2R receptors. Selective deletion of Y1R in osteoblasts or Y2R in the hypothalamus results in high bone mass, but deletion of PYY has resulted in conflicting skeletal phenotypes leading to uncertainty regarding its role in the regulation of bone mass. We hypot...

ea0026p211 | Pituitary | ECE2011

Gender-related differences in prolactinomas

Ramos-Prol A , Camara-Gomez R , Leon-de Zayas B , Beltran A , Simal J A , Argente-Pla M , del Olmo-Garcia M I , Merino-Torres J F

Introduction: It has been previously described that prolactinomas may have a more aggressive behaviour in men than in women.Methods: We performed a retrospective study in 59 patients diagnosed of prolactinoma (19 men). The variables collected were: age at diagnosis, clinical presentation, tumor size and stage (Hardy classification) and treatment response. The results were compared between both genders.Results: Age at diagnosis was ...

ea0019p180 | Endocrine tumours and neoplasia | SFEBES2009

Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer

Folkerd E , Attard G , Dearnaley D , Hunt J , Maier G , Molina A , Olmos D , Oomen N , Parker C , Reid A , Thompson E , De Bono J , Dowsett M

Abiraterone acetate is a potent, selective inhibitor of CYP17, a key enzyme that catalyses the conversion of pregnenolone to dehydroepiandrosterone (DHEA) and progesterone to androstenedione. Inhibition of this enzyme causes suppression of the synthesis of both androgens and oestrogens. Hence treatment with abiraterone acetate could impact on the development and progression of hormone-dependent breast and prostate cancers.In a phase I/II1,2 st...